Board of Directors

As former president and CEO of Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), Dr. Dhillon successfully created a vertically integrated DNA vaccine development company with one of the strongest development pipelines in the industry. Dr. Dhillon also raised over $125 million and secured more than $200 million in licensing deals from global companies including Merck and Wyeth (now Pfizer).

Dr. Dhillon was a founding board member of Protox Therapeutics, Inc. and currently sits on the Board of Directors of BC Advantage Funds, the largest Venture Capital Corporation in British Columbia.

Formerly the VP of finance and operations at Inovio Pharmaceuticals, Inc., Mr. Dhillon raised over $125 million through multiple financings and several licensing deals. He was also instrumental to the successful in-licensing of key intellectual property and a number of corporate transactions, including the acquisition and consolidation of Inovio AS, a Norwegian DNA delivery company, and the merger with VGX Pharmaceuticals.

Mr. Dhillon has also been a consultant and board member for several early stage life science companies.

Dr. DeMesa has been a practicing physician and served as a senior executive with several international pharmaceutical and biotech companies in the areas of corporate management, regulatory affairs, and pre-clinical and clinical pharmaceutical and medical device product development. Most recently, Dr. DeMesa served as president, CEO, and director of Migenix Inc., a public biotechnology company.

Dr. DeMesa was also president and CEO of GenSci Regeneration Sciences Inc., a public biotech company, and vice president of medical and regulatory affairs at Biodynamics International, Inc. He is also a co-founder of CommGeniX and MedXcel.

Most recently, Dr. Maida was vice president of clinical research and general manager of oncology, worldwide, for a leading international contract research organization.

He has served as president and CEO of both Replicon NeuroTherapeutics, Inc. and Jenner Therapies, interim CEO for Trellis Bioscience, Inc., and president of CancerVax Corporation, where he secured the Company’s first financing of $30 million.

Today, Dr. Maida serves as a senior advisor for multiple investment firms and life science companies. He also sits on the board of directors of Spectrum Pharmaceuticals, Inc.